The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021.
Mattias Lundin is currently the Vice President Global Sales of the world-leading, Swedish medical device company CellaVision, which offers digital imaging analyzers for diagnostics of blood and body fluids. Mattias Lundin has extensive international experience in the health care industry, including as CEO in the Nordic countries, CEO in the Netherlands and VP Commercial for mature markets at ArjoHuntleigh within the Getinge Group.
"It is time for Lumito to take the next step towards commercialization, and I am therefore very happy that we have been able to recruit Mattias Lundin to lead us as we continue our journey; Mattias Lundin will contribute experience from a number of commercial roles, and he is a team player with an impressive track record when it comes to building successful teams and expanding novel technology globally", says Masoud Khayyami, Chairman of the Board of Lumito.
Lumito is a life science company that has developed a medical device with unique and patented technology based on fluorescence from upconversion nanoparticles. The product aims to improve quality, free resources, increase precision and reduce the risk of human error in diagnostics of cancer indications. The focus is initially on digital pathology and tissue diagnostics.
"It will be exciting to join Lumito and get a feel for the opportunities and challenges, both in the short term and strategically. The company has an innovative and unique technology that fulfills a clear market need for fast and reliable diagnostics and offers pathologists a valuable resource in their fight against cancer and other diseases. I look forward to working with Lumito's skilled employees, board and future customers", says Mattias Lundin.
Urban Widén, who currently serves as the acting CEO of the Company, will return to his prior role as member of the board of Lumito when Mattias Lundin takes position.
"I would like to thank Urban Widén for an excellent effort during his months leading the work at Lumito, and we are pleased that he will remain on the company's board as a strong asset", says Masoud Khayyami.
For more information, please contact:
Lumito AB (publ), Chairman of the Board Masoud Khayyami, e-mail: firstname.lastname@example.org
This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out in this press release, at 08:45 CET on November 27, 2020.
The share is traded under the ticker LUMITO on the NGM Nordic SME, where the Company's mentor is G&W Fondkommission, telephone: +46(0)8-503 000 50.
specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. www.lumito.se